Gentium S.p.A. Announces Decision to Voluntarily Delist American Depositary Shares from The NASDAQ Global Market
March 05, 2014 14:49 ET
|
Gentium S.p.A.
VILLA GUARDIA (COMO), Italy, March 5, 2014 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT), a Jazz Pharmaceuticals company, today announced that it has notified the NASDAQ Stock Market of its...
Jazz Pharmaceuticals and Gentium S.p.A. Announce Agreement for Jazz Pharmaceuticals to Acquire Gentium for $57.00 Per Share
December 19, 2013 16:47 ET
|
Gentium S.p.A.
Transaction would add a significant growth product in the European Union and Rest of World markets, Defitelio™ (defibrotide), a treatment for severe hepatic veno-occlusive disease in adults...
Interim Results From Gentium's Treatment IND for Defibrotide and Additional Data on Defibrotide in the Prevention of Acute Graft Versus Host Disease (aGvHD) Presented at the American Society of Hematology Annual Meeting
December 11, 2013 07:00 ET
|
Gentium S.p.A.
VILLA GUARDIA (COMO), Italy, Dec. 11, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that additional data on Defibrotide were presented this week at the 55th...
Data From Non HSCT VOD Patients Treated With Defibrotide and a Treatment IND Update to be Presented at the American Society of Hematology 2013 Annual Meeting
November 26, 2013 07:00 ET
|
Gentium S.p.A.
VILLA GUARDIA (COMO), Italy, Nov. 26, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that an oral presentation and a poster on Defibrotide will be presented at...
Gentium Receives EMA Orphan Drug Designation for Defibrotide for the Prevention of GvHD
November 19, 2013 07:00 ET
|
Gentium S.p.A.
VILLA GUARDIA, Italy, Nov. 19, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that the European Commission ("EC") has granted Orphan Drug Designation to...
Defibrotide Granted Orphan Drug Status in Australia
November 14, 2013 07:00 ET
|
Gentium S.p.A.
VILLA GUARDIA (COMO), Italy, Nov. 14, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) and Link Healthcare today announced that Defibrotide has been designated as an Orphan Drug for the Treatment...
Gentium Announces Successful Completion of Defibrotide Phase 1 Study in Japan
November 12, 2013 07:00 ET
|
Gentium S.p.A.
VILLA GUARDIA (COMO), Italy, Nov. 12, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that the medical team from the Phase 1 Trial Unit of the Translational...
Gentium Reports Third Quarter 2013 Financial Results
October 31, 2013 06:00 ET
|
Gentium S.p.A.
EU commission grants Gentium Marketing Authorization for Defitelio® (defibrotide)
Defibrotide revenues up 41% and 72% to EUR 24.22 million (USD 32.71 million) and to EUR 9.96 million...
Gentium to Report Third Quarter 2013 Financial Results
October 28, 2013 07:45 ET
|
Gentium S.p.A.
VILLA GUARDIA (COMO), Italy, Oct. 28, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that it will report its financial results for the third quarter 2013 on...
Gentium Receives Marketing Authorization From the European Commission for Defitelio(R) (Defibrotide)
October 22, 2013 06:00 ET
|
Gentium S.p.A.
VILLA GUARDIA, Italy, Oct. 22, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that the European Commission has granted a Marketing Authorization for...